Minesapride, a novel 5-hydroxytryptamine 4 (5-HT4) receptor partial agonist, is a potential gastrointestinal prokinetic agent for the treatment of irritable bowel syndrome with constipation.

Sarizotan 2HCl is an hERG channel inhibitor and 5-hydroxytryptamine 5-HT1A receptor agonist with potential antidepressant effects for the study of Parkinsonian movement disorders.

Viloxazine (Viloxazin) 是一种去甲肾上腺素重摄取 (norepinephrine reuptake) 抑制剂，也是有效的 5-HT2C 激动剂和 5-HT2B 拮抗剂，对 5-HT2C 的 EC50 为 32 μM，对 5-HT2B 的 IC50 为 27 μM。Viloxazine 的作用机制主要涉及血清素能和去甲肾上腺素能通路。Viloxazine 可用于抗抑郁研究。